SCHEMBL13791925

SCHEMBL13791925

CC(C)(C)n1c2ccccc2c2cc(-c3ccc(-c4ccc(-c5c6ccccc6c(-c6ccc(-c7ccc(-c8ccc9c(c8)c8ccccc8n9C(C)(C)C)cc7)cc6)c6ccccc56)cc4)cc3)ccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSPO P30536 4/20 0.40
▸ KDM4E B2RXH2 4/20 0.35
▸ MAPT P10636 3/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ HPGD P15428 2/20 0.35
▸ HTT P42858 2/20 0.35
▸ HSD17B10 Q99714 2/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ NPY5R Q15761 3/20 0.35
▸ GPR3 P46089 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ HBB P68871 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ RXRA P19793 1/20 0.34
▸ RXRB P28702 1/20 0.34
▸ LMNA P02545 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ SERPINE1 P05121 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13762046 1.00 TSPO (0.40) TSPOKDM4EMAPTKMT2AMEN1
SCHEMBL13761871 0.97 TSPO (0.44) TSPOKDM4EKMT2ANPY5RRXRA
SCHEMBL13761876 0.97 TSPO (0.44) TSPOKDM4EKMT2ANPY5RRXRA
SCHEMBL13761878 0.97 TSPO (0.44) TSPOKDM4EKMT2ANPY5RRXRA
SCHEMBL13761877 0.97 TSPO (0.44) TSPOKDM4EKMT2ANPY5RRXRA
SCHEMBL13762045 0.97 TSPO (0.44) TSPOKDM4EKMT2ANPY5RRXRA
SCHEMBL13761870 0.97 TSPO (0.44) TSPOKDM4EKMT2ANPY5RRXRA
SCHEMBL13761866 0.97 TSPO (0.44) TSPOKDM4EKMT2ANPY5RRXRA
SCHEMBL13762048 0.90 SERPINE1 (0.37) TSPOMAPTALDH1A1NPY5RRXRA
SCHEMBL13762047 0.90 SERPINE1 (0.37) TSPOMAPTALDH1A1NPY5RRXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9972790-B2 Anthracene derivative, and light-emitting material, light-emitting element, light-emitting device, and electronic device using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2018-05-15 — — US disclosed
US-20150249220-A1 ANTHRACENE DERIVATIVE, AND LIGHT-EMITTING MATERIAL, LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, AND ELECTRONIC DEVICE USING THE SAME SEMICONDUCTOR ENERGY LAB (JP) 2015-09-03 — — US disclosed
US-9070883-B2 Anthracene derivative, and light-emitting material, light-emitting element, light-emitting device, and electronic device using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2015-06-30 — — US disclosed
US-20130253206-A1 ANTHRACENE DERIVATIVE, AND LIGHT-EMITTING MATERIAL, LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, AND ELECTRONIC DEVICE USING THE SAME SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2013-09-26 — — US disclosed
US-8475935-B2 — — 2013-07-02 — — US disclosed
WO-2009081800-A1 ANTHRACENE DERIVATIVE, AND LIGHT-EMITTING MATERIAL, LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, AND ELECTRONIC DEVICE USING THE SAME SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2009-07-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150249220-A1 ANTHRACENE DERIVATIVE, AND LIGHT-EMITTING MATERIAL, LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, AND ELECTRONIC DEVICE USING THE SAME CRY1, CYP1A1, CRY2 TSPO 2908/4885KDM4E 2169/4885MAPT 3489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback